Mazdutide Research: Dual GLP-1 and Glucagon Receptor Agonism Explained — Potential Benefits

Mazdutide, also known as IBI362 or LY3305677, is a peptide-based medication developed to influence two important hormone receptors involved in metabolism.

It belongs to a group of compounds called dual receptor agonists, meaning it activates two different biological pathways at the same time.

Mazdutide targets:

• GLP-1 receptors: Involved in appetite control, insulin secretion, and blood sugar regulation.
• Glucagon receptors: Involved in energy metabolism, glucose production, and the body's processing of stored nutrients.

Researchers are interested in mazdutide because combining these two pathways could provide metabolic benefits beyond those associated with GLP-1 activation alone.

Clinical trials have already demonstrated significant effects on body weight and blood glucose levels, while researchers continue investigating its potential effects on liver health, fat metabolism, and cardiovascular risk factors.

To understand mazdutide, it helps to understand the two hormones whose actions it imitates.

1. GLP-1: Appetite and Blood Sugar Regulation

GLP-1 stands for glucagon-like peptide-1. It is a naturally occurring hormone released by the intestines after eating.

GLP-1 helps the body regulate food intake and blood sugar through several mechanisms:

• Reduces appetite: Acts on pathways involved in hunger and fullness.
• Supports insulin release: Encourages insulin secretion when blood glucose is elevated.
• Slows gastric emptying: Delays how quickly food leaves the stomach.
• Reduces glucagon secretion: Helps limit unnecessary glucose production when blood sugar is elevated.

These effects help explain why GLP-1-based medications have become important in diabetes and obesity treatment.

2. Glucagon: Energy and Metabolic Regulation

Glucagon is another naturally occurring hormone, produced primarily by alpha cells in the pancreas.

Its most established function is helping maintain blood glucose levels, particularly during fasting.

However, glucagon also influences other metabolic processes, including:

• Liver glucose production.
• Fat metabolism.
• Amino acid metabolism.
• Energy balance.

Experimental evidence suggests that glucagon receptor activation may also increase energy expenditure in certain circumstances.

This is one reason researchers are investigating drugs that combine GLP-1 and glucagon receptor activity.

However, glucagon can also increase blood glucose production. Combining it with GLP-1 receptor activation is intended to balance these potentially competing effects.

3. Why Combine Both Receptors?

The idea behind mazdutide is relatively straightforward.

GLP-1 signaling helps reduce food intake and improve glucose control, while glucagon signaling may offer additional effects on metabolic activity.

Combined metabolic response: Investigated for body-weight reduction, glycemic control and cardiometabolic effects.

Conceptual comparison of receptor pathways, not proof of their independent contributions to clinical outcomes.

Several clinical studies have investigated mazdutide's potential benefits in people with obesity, overweight, and type 2 diabetes.

Some findings are supported by large randomized clinical trials, while others remain preliminary.

Weight reduction is one of the most extensively studied effects of mazdutide.

By activating GLP-1 receptors, mazdutide can influence appetite-related signaling and help reduce food intake.

Researchers have investigated whether adding glucagon receptor activity can produce further metabolic effects.

What Have Clinical Trials Found?

A 2025 phase 3 study published in the New England Journal of Medicine, known as GLORY-1, investigated mazdutide in 610 Chinese adults with overweight or obesity.

After 48 weeks, average body-weight changes were:

A separate phase 3 trial, GLORY-2, published in JAMA in 2026, examined a higher mazdutide dose in adults with obesity.

After 60 weeks, participants receiving mazdutide experienced an average weight reduction of 16.65%, compared with 1.50% for placebo.

These findings demonstrate substantial weight-loss effects under controlled clinical trial conditions. GLORY-1 and GLORY-2.

It is important to remember that these were supervised medical studies involving defined treatment protocols, not studies of independently sourced research products.

Mazdutide has also been investigated for its effects on blood glucose levels, particularly in people with type 2 diabetes.

GLP-1 receptor activation helps the pancreas release insulin in response to elevated blood glucose.

This can improve glucose regulation while limiting the likelihood of excessive insulin release when blood sugar is normal.

What Does the Research Show?

The DREAMS-1 phase 3 trial, published in Nature, investigated mazdutide in 320 adults with type 2 diabetes.

After 24 weeks, researchers observed the following changes in HbA1c, a measurement that reflects average blood glucose over approximately three months:

Participants receiving mazdutide also experienced greater average weight reduction than those receiving placebo.

The findings suggest that mazdutide can improve blood glucose management while simultaneously influencing body weight.

This combination is particularly interesting because obesity and type 2 diabetes frequently occur together. DREAMS-1.

Another emerging area of research concerns the effects of mazdutide on fat accumulation in the liver.

Excessive liver fat is associated with metabolic dysfunction and can contribute to conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD).

Glucagon receptors are strongly expressed in the liver, making this organ particularly interesting in dual-agonist research.

What Have Researchers Discovered?

An exploratory analysis of the GLORY-1 trial investigated liver fat using magnetic resonance imaging.

In participants whose liver fat was at least 10% at baseline, the mazdutide 6-mg group experienced an approximately 80.2% relative reduction in liver fat after 48 weeks.

This is a relative percentage change in measured liver fat, not an 80-percentage-point reduction.

These results suggest that mazdutide could have meaningful effects on liver fat accumulation. Exploratory GLORY-1 analysis.

However, this analysis was exploratory. More research is needed to establish whether mazdutide directly improves liver inflammation, fibrosis, or long-term liver disease outcomes.

One feature that makes mazdutide different from conventional GLP-1-only medications is its additional glucagon receptor activity.

Researchers have proposed that glucagon signaling might influence how the body uses energy and stored nutrients.

Potential mechanisms include:

• Changes in hepatic fat metabolism.
• Increased mobilization of certain energy substrates.
• Changes in energy expenditure.
• Alterations in metabolic signaling pathways.

Some animal studies and experiments with related dual agonists support these mechanisms.

Nevertheless, it has not been established that mazdutide independently increases resting energy expenditure in humans or that an increased metabolic rate explains its weight-loss results.

Its clinically demonstrated weight reduction should not be interpreted as proof of a direct fat-burning effect.

Researchers have also examined whether mazdutide influences markers associated with cardiovascular and metabolic health.

These include:

• Waist circumference.
• Blood pressure.
• Triglycerides.
• Cholesterol levels.
• Blood glucose regulation.

In the GLORY-2 trial, researchers reported improvements in several of these measurements alongside substantial weight reduction.

For example, at 60 weeks, average waist circumference decreased by approximately 12.82 cm in the mazdutide group, compared with 2.00 cm in the placebo group. Systolic blood pressure also declined more in the mazdutide group. GLORY-2.

These changes may be beneficial for overall metabolic health.

However, improvements in risk markers do not automatically demonstrate that a medication reduces heart attacks, strokes, or cardiovascular mortality. Dedicated long-term outcome studies are needed to establish those effects.

Mazdutide belongs to the broader family of peptide-based metabolic therapies, but its receptor activity differs from that of semaglutide and tirzepatide.

The key difference is that mazdutide combines GLP-1 activity with glucagon receptor activation rather than GIP receptor activation.

This creates a distinct biological profile that researchers hope may offer additional metabolic effects.

However, the number of receptors a compound targets does not necessarily determine its clinical effectiveness. Comparisons between these compounds require appropriately designed head-to-head trials.

Like other medicines that activate GLP-1 receptors, mazdutide can produce gastrointestinal adverse effects.

The most commonly reported include:

• Nausea.
• Vomiting.
• Diarrhea.
• Reduced appetite.
• Abdominal discomfort.

In the GLORY-2 trial, vomiting occurred in 53.1% of mazdutide recipients compared with 1.3% of placebo recipients. Nausea and diarrhea were also substantially more frequent in the treatment group.

Although most reported adverse events were mild to moderate, they can be significant and may lead some participants to discontinue treatment. GLORY-2.

Researchers continue investigating longer-term tolerability and safety, including effects on cardiovascular outcomes, gallbladder health, pancreatic complications, and changes in body composition.

Despite promising clinical results, several important scientific questions remain unanswered.

Long-Term Safety

Trials have generated valuable safety information, but the effects of treatment over many years are less well established.

Effects on Muscle Mass

Weight reduction can involve both fat and lean tissue. Researchers need further evidence to understand how mazdutide affects muscle preservation and body composition over time.

Long-Term Cardiovascular Benefits

Improvements in blood pressure, cholesterol, and body weight are encouraging, but researchers must establish whether these translate into fewer cardiovascular events.

Additional Benefits From Glucagon Activation

Mazdutide's dual mechanism is scientifically interesting, but researchers have not conclusively determined how much of its clinical weight-loss effect comes specifically from glucagon receptor activation.

What Happens After Treatment Stops?

Further research is necessary to understand how much weight is regained following discontinuation and whether improvements in metabolic measurements persist.

Mazdutide has received regulatory approval in China for specified indications involving weight management and type 2 diabetes.

However, regulatory authorization varies by country. Approval in China does not mean mazdutide is approved for medical use in the European Union or United States.

Its regulatory status, approved indications, and prescribing conditions should always be checked with the appropriate national or regional regulatory authority.

Research note: Clinical evidence from regulated pharmaceutical trials cannot establish the safety, sterility, identity, or effectiveness of products sold independently as research-use peptides. Mazdutide research should not be interpreted as instructions for self-administration.

Mazdutide represents an important development in research involving peptide-based metabolic therapies.

By combining GLP-1 and glucagon receptor activation, the compound targets biological pathways involved in appetite, glucose regulation, and energy metabolism.

Human clinical studies have demonstrated substantial weight reduction and improvements in blood sugar control, particularly in populations with obesity or type 2 diabetes.

Additional findings suggest possible benefits for liver fat accumulation, blood pressure, waist circumference, and other cardiometabolic markers.

However, some proposed advantages, particularly increased energy expenditure and direct benefits from glucagon receptor activation, remain incompletely understood.

Overall, mazdutide is a promising example of how dual-receptor peptide therapies may expand approaches to metabolic disease. Continued clinical research will help determine its long-term effectiveness, safety, and potential advantages over existing treatments.

1. Ji L, et al. (2025). Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. New England Journal of Medicine.
2. Gao L, et al. (2026). Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA.
3. (2023). A Phase 2 Randomised Controlled Trial of Mazdutide in Chinese Overweight Adults or Adults With Obesity. Nature Communications.
4. (2026). Efficacy and Safety of Mazdutide in Adults With Obesity or Overweight: A US-Based Phase 2 Trial. The Lancet Diabetes & Endocrinology.
5. (2022). A Phase 1b Randomised Controlled Trial of IBI362 in Chinese Patients With Type 2 Diabetes. Nature Communications.
6. (2025). Mazdutide Versus Placebo in Chinese Adults With Type 2 Diabetes. Nature.
7. (2025). Mazdutide Versus Dulaglutide in Chinese Adults With Type 2 Diabetes. Nature.
8. (2024). Improvement of Liver Steatosis by Mazdutide in Chinese Participants With Overweight or Obesity: An Exploratory Analysis of GLORY-1. Diabetes.
9. (2024). Efficacy and Safety of Mazdutide on Weight Loss Among Diabetic and Non-Diabetic Patients. Frontiers in Endocrinology.
10. (2024). Glucagon Agonism in the Treatment of Metabolic Diseases Including Type 2 Diabetes Mellitus and Obesity. Diabetes, Obesity and Metabolism.
11. (2015). Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon + GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. Journal of Clinical Endocrinology & Metabolism.
12. (2026). Efficacy and Safety of Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes. Diabetes, Obesity and Metabolism.